Clinical efficacy of tiotropium in children with asthma
Juan Huang1, Ying Chen2, Zhen Long3, Xiaoqin Zhou4, Junhua Shu5

ABSTRACT
Objective: To investigate the clinical efficacy of tiotropium in children with asthma.
Methods: Eighty children with newly diagnosed moderate persistent asthma were enrolled into this study. The children were randomly assigned to the fluticasone propionate aerosol group or the fluticasone propionate aerosol plus tiotropium group for 12 weeks.
Results: Lung function was significantly improved in both groups at 4, 8, and 12 weeks compared with baseline (P < 0.01). Moreover, lung function was significantly improved in the tiotropium group compared with the control group (P < 0.05). However, there was no significant difference in the incidence of severe asthma between the two groups (36.3% and 26.8%, respectively; P > 0.05). Compared with the control group, the number of days and frequency of short-acting beta2-adrenoceptor agonist use was significantly reduced in the tiotropium group (P < 0.05). Awakenings during the night were also significantly decreased (P < 0.00). There were no severe adverse reactions in either of the study groups.
Conclusion: Tiotropium could significantly improve lung function, reduce the use of short-acting beta2-adrenoceptor agonists, and improve sleep in children with asthma. Furthermore, few adverse reactions were reported.

KEY WORDS: Anticholinergic agent, Asthma, Children, Tiotropium.

doi: http://dx.doi.org/10.12669/pjms.322.8836

How to cite this:
Huang J, Chen Y, Long Z, Zhou X, Shu J. Clinical efficacy of tiotropium in children with asthma. Pak J Med Sci. 2016;32(2):462-465.
doi: http://dx.doi.org/10.12669/pjms.322.8836

In USA, about 7 million children and adolescents suffer from asthma,1 in the UK, one in every seven children aged 2-15 has asthma symptoms requiring regular treatment2 and in China, about 232 in every 10 thousand children under 14 years in the urban has asthma, the rate is more higher than 10 years ago (which is 154 in every 10 thousand).3

Inhaled glucocorticoids are considered the first-line treatment for patients with asthma.4,5 But many patients taking an inhaled glucocorticoid are inadequately controlled which represents a significant healthcare concern.6,7 In combination with inhaled long-acting beta2-adrenoceptor agonists (LABAs) can improve asthma control in children.8 However, the long-term use of LABAs is associated with tolerance to the protective effects on the bronchi and an increased risk of fatal asthma exacerbations. The US Food and Drug Administration (FDA) have concerns regarding the safety of LABAs and
they recommend that patients discontinue LABAs upon control of asthma symptoms. They also recommend that patients discontinue LABAs upon control of asthma symptoms. So alternative medications for bronchospasm relief are required.

Tiotropium is a long-acting anticholinergic bronchodilator and many researchers consider the effect of tiotropium to be superior to that of LABA, which was effective in COPD. Recently several studies have demonstrated that tiotropium is effective in the treatment of asthma in adults and adolescents. Here we report our data on evaluating the efficacy and safety of tiotropium in children. We observed the effects on lung function, exacerbation frequency, awakening during the night, and other endpoints during a 12-week period in children with asthma.

**METHODS**

Eighty children aged 6-14 years (mean: 10.2±3.6 years) who were diagnosed with moderate persistent asthma in our hospital between December 2013 and December 2014 were enrolled into this study. All the children conformed to the 2008 diagnostic criteria of childhood asthma from the national pediatric asthma association. Eligible children had not received systemic corticosteroids, beta2-adrenoceptor agonists, or cholinergic receptor antagonists for four weeks before enrolment into the study. None of the children had contraindications for corticosteroids use, hypertension, heart disease, or glaucoma. This study was conducted in accordance with the declaration of Helsinki. Approval from the Ethics Committee of Hubei Maternal and Child Health Care Hospital. Written informed consent was obtained from all participants’ guardians. Additionally, the children could use the metered dose inhaler and inhalation system for tiotropium correctly.

The 80 children were randomly assigned to receive either 125 μg fluticasone propionate aerosol twice daily plus placebo once daily (control group), or 125 μg fluticasone propionate aerosol twice daily plus 18 μg tiotropium dry-powder inhaler once daily (treatment group). The study duration was 12 weeks. If the children experienced acute asthma symptoms during the study, short-acting beta2-adrenoceptor agonists, such as 100 μg albuterol aerosol, were permitted as rescue medication.

**Lung function testing:** Lung function testing was performed using a Jaeger MasterScreen pulmonary function testing system (Germany) to examine the tidal breathing flow volume curve at weeks 0 (baseline), 4, 8, & 12. Lung function tests included FEV1 (%), FVC, and PEF.

**Incidence of severe asthma:** Severe asthma was defined as an exacerbation that required treatment with oral corticosteroids or hospitalization, or where lung function was reduced by 30% compared to baseline. If severe asthma occurred more than twice within the 12-week study period, patients were withdrawn from the study. The frequency of use and number of days of use of short-acting beta2-adrenoceptor agonists were recorded. Nighttime awakenings were also recorded.

**Statistical analysis:** Statistical analysis was performed using SPSS 10.0 software. The results are presented as mean±SD. A paired t-test was used to analyze count data, and a chi-square test was used to analyze between-group probability. A p-value of <0.05 was considered statistically significant.

**Inclusion Criteria:** 1. Newly diagnosed moderate persistent asthma; 2. Can use the HandiHaler properly; 3. Without use of any glucocorticoid within 4 weeks and without use of any beta2-adrenoceptor agonists within one week; 4. No hormone contraindications.

**Exclusion Criteria:** Those who have heart disease, lung infection disease, glaucoma or other complications.

**RESULTS**

Two children in each of the study groups were withdrawn from the study following >2 severe asthma exacerbations. Therefore, four cases were not included in the statistical analysis. As shown in Table-I, there were no significant differences for BMI, age, and lung function between the 2 groups (P > 0.05).

| Groups       | n  | Male: Female | BMI    | Age     | FVC(L) | PEF %  | FEV1%  |
|--------------|----|--------------|--------|---------|--------|--------|--------|
| Control group| 40 | 24:16        | 18.2±3.0 | 10.1±4.8 | 1.55±0.56 | 68.57±3.42 | 67.41±8.51 |
| Treatment group | 40 | 25:15        | 18.5±3.1 | 9.3±5.2 | 1.53±0.47 | 69.88±3.55 | 67.31±7.32 |

Table-I: Comparisons of BMI, age and lung function between two groups (X±s).
The FEV\textsubscript{1}%, FVC, and PEF% of patients in both groups were significantly improved at weeks 4, 8, and 12 compared to baseline \((P < 0.01; \text{Table-II})\). Moreover, the improvement in lung function in the treatment group was significantly greater than in the control group (FEV\textsubscript{1}% at week 12 and FVC at week 8 \(P < 0.05\), all other indicators \(P < 0.01\)).

The incidence of severe asthma was 36.8\% (n=14/38) in the control group and 26.3\% (n=10/38) in the treatment group, but the difference between the two groups was not significant \((\chi^2=0.54, P > 0.05)\). Two patients who presented with severe asthma in each of the study groups were withdrawn from the study.

The frequency and number of days of use of on-demand short-acting beta\textsubscript{2}-adrenoceptor agonists were significantly reduced in the treatment group compared to the control group \((P < 0.05; \text{Table-III})\). Furthermore, significantly fewer night-time awakenings were reported in the treatment group compared to the control group \((P < 0.00)\).

**Adverse reactions:** In the treatment group, there were three reports of adverse reactions. All three patients presented with xerostomia and throat discomfort; however, the symptoms were relieved when the children were given more water and instructed to gargle water after administration of the medication. There were 2 adverse reactions reported in the control group. One patient presented with hoarseness, and another presented with thrush, which was successfully treated with mycin and oral nursing. There were no reports of hypertension, tachycardia, or glaucoma in either of the study groups.

**DISCUSSION**

FEV\textsubscript{1}%, FVC and PEF% are the standard parameter of lung functions. Our results show that, inhaled corticosteroids can improve the lung function of both the control and treatment groups, the result was the same with Pauwels.\textsuperscript{19} When added with tiotropium the lung function of treatment group was improved better than placebo. The result should be connected with tiotropium’s subtype selectivity.\textsuperscript{20} Vogelberg’s nearest study had demonstrated similar effects on children, although the end point was not the same with us.\textsuperscript{21}

Awakening during the night is an important factor that affects quality of life in all patients with asthma, including children. A large-scale investigation by Warvik\textsuperscript{22} found that 39\% of patients with asthma were woken every night due to symptoms, and 74\% of patients reported awakening at night at least once a week. Furthermore, 70\% of deaths due to asthma happen at night during sleep. Our study found that the tiotropium can reduce the frequency and the days of using the short-acting beta\textsubscript{2}-adrenoceptor agonists and also reduce the awakening days during the night. The reason may be that the parasympathetic nervous system is an important mechanism in nocturnal asthma symptoms\textsuperscript{23} and the long half-life of tiotropium which is nearly 35 hours and the efficacy can last for a whole day.\textsuperscript{24} Vogelberg’s research had not mentioned it.\textsuperscript{21}

Some studies show that the addition of tiotropium can significantly reduced the risk of episodes of the worsening. Our study showed the incidence of severe asthma was lower in the treatment group than in the control group, but the difference between the two groups was not significant. Therefore, a beneficial effect of tiotropium on the risk of severe asthma could not be proved. We think there may be other causal factors of severe asthma exacerbations, for example, allergic rhinitis and nasosinusitis, can complicate treatment.\textsuperscript{25}

| Groups       | Case | FEV1%     | FVC(L) | PEF%     |
|--------------|------|-----------|--------|----------|
|              |      | 4th week  | 8th week| 12th week|
|              |      | 4th week  | 8th week| 12th week|
|              |      | 4th week  | 8th week| 12th week|
| Control      | 38   | 73.91±5.66| 82.34±5.02| 87.5±5.76  |
| Treatment    | 38   | 79.56±7.01| 87.44±6.74| 91.61±5.73 |

\(\Delta\) vs before the treatment \(P < 0.01\); * vs. control group \(P < 0.05\), # \(P < 0.01\).

**Table II:** Changes of FEV1%, FVC and PEF% before and after treatment in two groups (\(\bar{X}\pm s\)).

\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|c|c|}
\hline
Groups       & Case & FEV1% & FVC(L) & PEF% & FEV1% & FVC(L) & PEF% & FEV1% & FVC(L) & PEF% & FEV1% & FVC(L) & PEF% \\
\hline
Control      & 38   & 73.91±5.66 & 82.34±5.02 & 87.5±5.76 & 1.63±0.47 & 1.70±0.51 & 1.80±0.59 & 77.39±3.56 & 81.63±4.76 & 86.35±3.65 & 1.63±0.47 & 1.70±0.51 & 1.80±0.59 \\
Treatment    & 38   & 79.56±7.01 & 87.44±6.74 & 91.61±5.73 & 1.87±0.42 & 1.95±0.48 & 2.42±0.55 & 80.0±3.68 & 85.52±3.9 & 89.67±4.14 & 1.87±0.42 & 1.95±0.48 & 2.42±0.55 \\
\hline
\end{tabular}

**Table III:** Comparisons of frequency and days of use of short acting beta 2 receptor agonist on demand and awakening days during the night (\(\bar{X}\pm s\)).

\begin{tabular}{|c|c|c|c|c|c|}
\hline
Groups       & Cases & Frequency & Days & Awakening days during the night \\
\hline
Control group & 38 & 0.65±0.34 & 42.1±16.5 & 45.1±10.6 \\
Treatment group & 38 & 0.51±0.23* & 32.9±14.3* & 28.4±6.9** \\
\hline
\end{tabular}

\(\ast\) vs. control group \(*P < 0.05\), \(**P < 0.0\).
In conclusion, tiotropium, a long-acting cholinergic receptor antagonist, could significantly improve lung function, reduce the need for on-demand short-acting beta2-agonist treatments, and improve nocturnal symptoms in children with asthma. Furthermore, tiotropium was associated with few adverse reactions in this patient group. These advantages indicate that tiotropium could be a promising prospect for the future for the treatment of asthma in children.

ACKNOWLEDGEMENT
Natural Science Funding of Science and Technology Department of Hubei Province: The efficacy and safety of the anticholinergic drug-tiotropium in children with asthma (2013CFB048).

Declaration of interest: All the authors declare that they have no conflicts of interest.

REFERENCES
1. 2011 National Health Interview Survey (NHIS) Date. 2011 Lifetime Asthma, Current Asthma, Asthma Attacks among those with Current Asthma [http://www.cdc.gov/asthma/nhis/2011/date.htm].
2. Lung health in Europe: facts and figures [http://www.europeanlung.org/assets/files/en/publications/lung-health-in-europe-facts-and-figures-web-vfour.pdf].
3. National Cooperative Group of Pediatric Asthma. Chinese Center for Disease Control Environmental Health and Related Product Safety. Third Nationwide survey of childhood asthma in urban areas of China. Chinese Journal of Pediatrics. 2013;51(10):729-735.
4. Global Initiative for Asthma. Global strategy for asthma management and prevention. Washington DC: National Heart, Lung, and Blood Institute. 1995.9 (Publication no.95-3659).
5. Erika VM, Jeffrey M, Drazen A. Patient with Asthma Seeks Medical Advice in 1828, 1928, and 2012. N Engl J Med. 2012;367:1040-1045.
6. Liu AH, Gilsenan AW, Stanford RH, William L, Ryan Z, Hector O, et al. Status of asthma control in pediatric primary care: results from the pediatric Asthma Control Characteristics and Prevalence Survey Study (ACCESS). J Pediatr. 2010;157:276-281.
7. Bodzenta-Lukaszyk A, van Noord J, Schröder-Babo W, McAulay K, McVicr T. Efficacy and safety profile of fluticasone/salmeterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial. Curr Med Res Opin. 2013;29(5):579-588.
8. Drape JM, O’Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009;360:1671-1672.
9. Rockville. Food and drug administration: Long-acting beta agonist (LABA) information [EB/OL]. [2013-03-10] http://www.fda.gov/Drug/Drugsafety/Informationbydrugclass/ucm199565.html.
10. Barnes PJ, Belvisi MG, Mak JC, Haddad EB, O’Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 1995;56(11-12):853-859.
11. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B6f-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315-322.
12. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleeker E, Boushey HA, Calhoun WJ, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): A genotype-stratified, randomized, placebo-controlled, crossover trial. Lancet. 2009;374(9703):1754-1764.
13. Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest. 2012;141(1):81-86.
14. Tashkin DP, Celli B, Stephen S, Deborah B, Steven K, Shaileendra M, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
15. Kerstjens HAM, Disse B, Schroder-Bantje W, Bantje TA, Martina G, Ralf S, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128:308-314.
16. Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Urseld A, Engel M, et al. Tiotropium Respimat in asthma: a double-blind, randomized,dose-ranging study in adult patients with moderate asthma. Respir Res. 2014;15:1-9.
17. Christian V, Michael E, Petra MZ, Ralf S, John D, Katja N, et al. Tiotropium in asthma adolescents symptomatic despite inhaled corticosteroids: a randomized dose-ranging study. Respir Med. 2014;161:1268-1279.
18. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405-1411.
19. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilatation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136-1142.
20. Vogelberg C, Moroni-Zentgraf P, Sigmund R, Hamelmann E, Engel M, Zeefler S. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respiratory Res. 2015:16:1-10.
21. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med. 1988;85(1B):6-8.
22. Morrison JF, Pearson SB, Dean HG. Parasympathetic nervous system in nocturnal asthma. Br Med J (Clin Res Ed). 1988;296(6634):1427-1429.
23. Casaburi R, Mahler DA, Jones PW, Wanner A, Sam PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
24. Boussquet J, Cauwenberge PV, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:5147-5334.

Author’s Contributions:
JH: concept, analysis of data, writing this paper and final approval of the manuscript.
YC: Analysis of data, writing and revision of the article.
ZL: Designed this study, drafting the article, revising it critically for important intellectual content.
XZ: Collection, analysis of data and interpretation.
JS: Collecting of data and final approval of the manuscript.